This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Dec;13(12):e518-9.

doi: 10.1016/S1470-2045(12)70426-6.

TAS-102: more than an antimetabolite

Godefridus J Peters, Irene V Bijnsdorp

PMID: 23182191
DOI: 10.1016/S1470-2045(12)70426-6

Comment

TAS-102: more than an antimetabolite

Godefridus J Peters et al. Lancet Oncol. 2012 Dec.

. 2012 Dec;13(12):e518-9.

doi: 10.1016/S1470-2045(12)70426-6.

Authors

Godefridus J Peters, Irene V Bijnsdorp

PMID: 23182191
DOI: 10.1016/S1470-2045(12)70426-6

No abstract available

PubMed Disclaimer

Comment on

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Yoshino T, et al. Lancet Oncol. 2012 Oct;13(10):993-1001. doi: 10.1016/S1470-2045(12)70345-5. Epub 2012 Aug 28. Lancet Oncol. 2012. PMID: 22951287 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information